BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Akhtar R, Chandel S, Sarotra P, Medhi B. Current status of pharmacological treatment of colorectal cancer. World J Gastrointest Oncol 2014; 6(6): 177-183 [PMID: 24936228 DOI: 10.4251/wjgo.v6.i6.177] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Basu S, Zeng M, Yin T, Gao S, Hu M. Development and validation of an UPLC-MS/MS method for the quantification of irinotecan, SN-38 and SN-38 glucuronide in plasma, urine, feces, liver and kidney: Application to a pharmacokinetic study of irinotecan in rats. J Chromatogr B Analyt Technol Biomed Life Sci 2016;1015-1016:34-41. [PMID: 26894853 DOI: 10.1016/j.jchromb.2016.02.012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
2 Martchenko K, Schmidtmann I, Thomaidis T, Thole V, Galle PR, Becker M, Möhler M, Wehler TC, Schimanski CC. Last line therapy with sorafenib in colorectal cancer: A retrospective analysis. World J Gastroenterol 2016; 22(23): 5400-5405 [PMID: 27340356 DOI: 10.3748/wjg.v22.i23.5400] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
3 Milczarek M, Pogorzelska A, Wiktorska K. Synergistic Interaction between 5-FU and an Analog of Sulforaphane-2-Oxohexyl Isothiocyanate-In an In Vitro Colon Cancer Model. Molecules 2021;26:3019. [PMID: 34069385 DOI: 10.3390/molecules26103019] [Reference Citation Analysis]
4 Bakhrebah MA, Nasrullah M, Abdulaal WH, Hassan MA, Siddiqui H, Al Doghaither H, Omar UM, Helmi N, Fallatah MM, Al-Ghafari AB, Khan MI, Choudhry H. High Expression of Pd-1 in Circulating Cells of Patients With Advanced Colorectal Cancer Receiving Adjuvant Therapy. Technol Cancer Res Treat 2020;19:1533033820969446. [PMID: 33153413 DOI: 10.1177/1533033820969446] [Reference Citation Analysis]
5 Vinette V, Placet M, Arguin G, Gendron FP. Multidrug Resistance-Associated Protein 2 Expression Is Upregulated by Adenosine 5'-Triphosphate in Colorectal Cancer Cells and Enhances Their Survival to Chemotherapeutic Drugs. PLoS One 2015;10:e0136080. [PMID: 26295158 DOI: 10.1371/journal.pone.0136080] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
6 Goldvaser H, Katz Shroitman N, Ben-Aharon I, Purim O, Kundel Y, Shepshelovich D, Shochat T, Sulkes A, Brenner B. Octogenarian patients with colorectal cancer: Characterizing an emerging clinical entity. World J Gastroenterol 2017; 23(8): 1387-1396 [PMID: 28293085 DOI: 10.3748/wjg.v23.i8.1387] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
7 Falzone L, Scola L, Zanghì A, Biondi A, Di Cataldo A, Libra M, Candido S. Integrated analysis of colorectal cancer microRNA datasets: identification of microRNAs associated with tumor development. Aging (Albany NY) 2018;10:1000-14. [PMID: 29779016 DOI: 10.18632/aging.101444] [Cited by in Crossref: 82] [Cited by in F6Publishing: 87] [Article Influence: 41.0] [Reference Citation Analysis]
8 Chien TW, Chang Y, Wen KS, Uen YH. Using graphical representations to enhance the quality-of-care for colorectal cancer patients. Eur J Cancer Care (Engl) 2018;27. [PMID: 27778444 DOI: 10.1111/ecc.12591] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
9 Milone MR, Pucci B, Colangelo T, Lombardi R, Iannelli F, Colantuoni V, Sabatino L, Budillon A. Proteomic characterization of peroxisome proliferator-activated receptor-γ (PPARγ) overexpressing or silenced colorectal cancer cells unveils a novel protein network associated with an aggressive phenotype. Mol Oncol 2016;10:1344-62. [PMID: 27499265 DOI: 10.1016/j.molonc.2016.07.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
10 Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. Pharmacol Ther 2020;206:107447. [PMID: 31756363 DOI: 10.1016/j.pharmthera.2019.107447] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 36.5] [Reference Citation Analysis]
11 Theiner S, Kornauth C, Varbanov HP, Galanski M, Van Schoonhoven S, Heffeter P, Berger W, Egger AE, Keppler BK. Tumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(IV)-based anticancer agents. Metallomics 2015;7:1256-64. [PMID: 25856224 DOI: 10.1039/c5mt00028a] [Cited by in Crossref: 29] [Cited by in F6Publishing: 7] [Article Influence: 4.8] [Reference Citation Analysis]
12 Buck A, Halbritter S, Späth C, Feuchtinger A, Aichler M, Zitzelsberger H, Janssen KP, Walch A. Distribution and quantification of irinotecan and its active metabolite SN-38 in colon cancer murine model systems using MALDI MSI. Anal Bioanal Chem 2015;407:2107-16. [PMID: 25311193 DOI: 10.1007/s00216-014-8237-2] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 8.1] [Reference Citation Analysis]
13 Sophonnithiprasert T, Mahabusarakam W, Watanapokasin R. Artonin E sensitizes TRAIL-induced apoptosis by DR5 upregulation and cFLIP downregulation in TRAIL-refractory colorectal cancer LoVo cells. J Gastrointest Oncol 2019;10:209-17. [PMID: 31032087 DOI: 10.21037/jgo.2018.12.02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Dong W, Cao Z, Pang Y, Feng T, Tian H. CARF, As An Oncogene, Promotes Colorectal Cancer Stemness By Activating ERBB Signaling Pathway. Onco Targets Ther 2019;12:9041-51. [PMID: 31802911 DOI: 10.2147/OTT.S225733] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
15 Jinendiran S, Dahms HU, Dileep Kumar BS, Kumar Ponnusamy V, Sivakumar N. Diapolycopenedioic-acid-diglucosyl ester and keto-myxocoxanthin glucoside ester: Novel carotenoids derived from Exiguobacterium acetylicum S01 and evaluation of their anticancer and anti-inflammatory activities. Bioorg Chem 2020;103:104149. [PMID: 32861993 DOI: 10.1016/j.bioorg.2020.104149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
16 Goldvaser H, Purim O, Kundel Y, Shepshelovich D, Shochat T, Shemesh-Bar L, Sulkes A, Brenner B. Colorectal cancer in young patients: is it a distinct clinical entity? Int J Clin Oncol. 2016;21:684-695. [PMID: 26820719 DOI: 10.1007/s10147-015-0935-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
17 Wang X, Wang J, Wu J. Emerging roles for HMGA2 in colorectal cancer. Transl Oncol 2021;14:100894. [PMID: 33069103 DOI: 10.1016/j.tranon.2020.100894] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
18 Abdellateif MS, Salem SE, Badr DM, Shaarawy S, Hussein MM, Zekri AN, Fouad MA. The Prognostic Significance of 5-Fluorouracil Induced Inflammation and Immuno-Modulation in Colorectal Cancer Patients. J Inflamm Res 2020;13:1245-59. [PMID: 33408498 DOI: 10.2147/JIR.S283069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Wang W, Zhang L, Morlock L, Williams NS, Shay JW, De Brabander JK. Design and Synthesis of TASIN Analogues Specifically Targeting Colorectal Cancer Cell Lines with Mutant Adenomatous Polyposis Coli (APC). J Med Chem 2019;62:5217-41. [PMID: 31070915 DOI: 10.1021/acs.jmedchem.9b00532] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]